
Schizophrenia
Latest News
Latest Videos

CME Content
More News



















Antipsychotic dose reductions can increase mental illness and all-cause hospitalizations, but the effects on tardive dyskinesia were unclear.

Recent studies questioned the benefits of second-generation antipsychotics, prompting researchers to reassess the risks of tardive dyskinesia from the use of first- and second-generation antipsychotics.

Study findings may facilitate new studies on the neural markers of tardive dyskinesia.

Meeting with a peer support worker to complete a personal recovery workbook reduced readmissions over a year for patients with mental health challenges.

The long-acting injectable risperidone (Perseris) will provide an alternative to daily oral medication to improve treatment adherence for patients with schizophrenia.

Three-quarters of patients who discontinue antipsychotic treatment experience relapse within 12-18 months. However, there are no current clinical guidelines describing treatment continuation or discontinuation beyond 1-2 years.

The new formulation allows patients with schizophrenia to begin treatment with just one oral dose of aripiprazole, achieving relevant levels in 4 days.



























































